<DOC>
	<DOCNO>NCT00191425</DOCNO>
	<brief_summary>The primary purpose study compare 3 different osteoporosis therapy follow one year teriparatide.In first year , eligible patient receive open-label teriparatide 20 micrograms/day.After 1 year , patient randomly assign one 3 possible follow-up treatment regimens second 12 month : continuation teriparatide , switch raloxifene , pharmacological treatment ( calcium vitamin D supplement everyone receives ) . Patients stratify 3 subset : ( ) patient never receive anti-osteoporosis treatment ; ( b ) patient receive prior antiresorptive treatment successfully ; ( c ) patient fail respond adequately prior antiresorptive drug ( bisphosphonates raloxifene ) past . These latter patient randomize month 12 continue treatment teriparatide 20 micrograms/day throughout second year .</brief_summary>
	<brief_title>2-Year Therapy With Teriparatide v 1-yr Therapy Followed 1-Year Raloxifene Calcium/Vit D Severe Postmenopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Ambulatory woman great equal 55 year , least 2 year postmenopausal . Lumbar spine total hip femoral neck bone mineral density measurement must least 2.5 standard deviation ( SD ) average bone mass young woman ( Tscore 2.5 less ) . Presence least one know document preexist clinical fragility fracture , past 3 year . Patients may include substudy 2 meet one follow additional criterion Patients sustain least one new fragility fracture ( vertebral nonvertebral ) , despite prescription antiresorptive therapy* 12 month prior last new fracture patient , minimum two year initiate antiresorptive therapy* , either lumbar spine , femoral neck , total hip BMD least 3SD average bone mass young woman ( Tscore 3 less ) , show decrease least 3.5 % BMD one sit . *Antiresorptive therapy include bisphosphonates , raloxifene , ERT/HRT , calcitonin , vitamin D metabolite . For substudy 1 patient : current history vaginal bleeding spot unknown cause 1 year prior study start currently suspect history venous thrombotic event ( VTE ) , include low extremity thrombosis , major venous thromboses , high risk develop VTE assessment investigator . Treatment Vitamin D &gt; 50,000 IU/week dose calcitriol vitamin D analogs agonists 6 month prior visit 2 Fluorides 12 month prior visit 2 . Systemic corticosteroid ( replacement therapy ) 1 month prior visit 2 . ( Ophthalmic , otic topical , orally inhale , nasally inhale , intraarticular corticosteroid therapy may use without restriction . )</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>